University Hospital Of Canary Islands

Research site

Spain Carretera De La Cuesta Taco S/n, Cuesta La, 38320 San Cristobal De La Laguna, Spain

10 trials recruiting
Breast cancer · HER2 positive breast cancer · Asthma
Adults and children

About Specializations

University Hospital Of Canary Islands in San Cristobal De La Laguna, Spain specialises in clinical trials of conditions such as Breast cancer, HER2 positive breast cancer, Asthma, Chronic lymphocytic leukaemia, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Carretera De La Cuesta Taco S/n, Cuesta La38320 San Cristobal De La LagunaSpain

Open in maps ↗

Recruiting now: 10 trials
Conditions studied: 32

More sites in San Cristobal De La Laguna Spain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

33 clinical trials

Squamous cell carcinoma of lung+6

Recruiting

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:BNT327
Sponsor:BioNTech SE

Contact Research Centre

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Sargramostim
Sponsor:Greenwich LifeSciences Inc.

Contact Research Centre

Asthma

Recruiting

A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma

Investigational

A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Kymera Therapeutics Inc.

Contact Research Centre

HER2 positive breast cancer

Recruiting

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pertuzumab
Sponsor:Solti Group

Contact Research Centre

Renal transplant

Recruiting

Study on the Impact of Acetylcysteine and Drug Combination on Kidney Function in Living Donor Kidney Transplant Patients

Registered drugNo placebo

Study on the Impact of Acetylcysteine and Drug Combination on Kidney Function in Living Donor Kidney Transplant Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Acetylcysteine
Sponsor:University Hospital Of Canary Islands

Contact Research Centre

Neoplasm malignant

Recruiting

Study of ART6043, Olaparib, and Niraparib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

Study of ART6043, Olaparib, and Niraparib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:ART6043
Sponsor:Artios Pharma Limited

Contact Research Centre

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Cisplatin
Sponsor:Centre Leon Berard

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Dermatomyositis+1

Recruiting

Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

Registered drug

Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Pfizer Inc.

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anhydrous Caffeine
Sponsor:UCB Biopharma

Contact Research Centre

Asthma

Not yet recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Sponsor:Kymera Therapeutics Inc.

Contact Research Centre

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites